Nisha Pandey

Health and Me

Can Obeldesivir Prevent Ebola Symptoms After Exposure? Drug Trial Moves Forward As Death Toll Crosses 4,000

Congo Ebola Outbreak: Obeldesivir Trial Advances With 250+ Participants As Death Toll Crosses 4,000

An experimental antiviral drug, obeldesivir, is being tested in the Democratic Republic of Congo to assess whether it can prevent <a href="https://www.healthandme.com/health/ebola">Ebola</a> from developing further after a person has been exposed to the virus.

As the country continues to fight the deadliest Ebola outbreak, more than 250 people have now enrolled in the EBO-PEP trial, which is testing obeldesivir, an oral antiviral developed by Gilead Sciences.

The trial is being conducted in Ituri province, the epicentre where the outbreak caused by the Bundibugyo strain of Ebola is concentrated. 

According to Congolese health authorities, until now, more than 8,300 confirmed cases and 4,000 deaths across seven provinces have been recorded. 

<h2>More About Obeldesivir Trial </h2>

Also read: <a href="https://www.healthandme.com/health-news/russia-plague-scare-lab-worker-dies-of-unknown-infection-after-suspected-exposure-cdc-monitors-the-situation-article-156274150" data-type="tilCustomLink">Russia Plague Scare: Lab Worker Dies Of 'Unknown Infection' After Suspected Exposure; CDC Monitors The Situation</a>

Obeldesivir is not being given to people who are already sick with <a href="https://www.healthandme.com/health-news/mpox-case-detected-in-congos-ituri-amid-ebola-outbreak-why-are-health-officials-concerned-article-156235757" data-type="tilCustomLink">Ebola</a> in this trial. Instead, researchers are testing it as post-exposure prophylaxis, or PEP.

PEP means treating someone after they have been exposed to an infection but before they develop symptoms. 

The EBO-PEP trial is enrolling people who have had high-risk contact with a confirmed Ebola patient within the previous five days but do not have symptoms. Participants are randomly assigned to receive either obeldesivir or a placebo and are monitored for 21 days, with follow-up continuing to 42 days. The obeldesivir study is designed to include 998 people. 

The ongoing Ebola outbreak in Ebola is caused by Bundibugyo ebolavirus, a strain for which there is currently no licensed vaccine or approved treatment. 

In May, WHO experts identified obeldesivir as a candidate for testing as post-exposure prophylaxis. They recommended that it be studied to establish whether it can actually prevent people exposed to the virus from developing Ebola. 

WHO chief scientist Dr Sylvie Briand said at the time, “This is a promising treatment drug, but it has still to be implemented under a very, very strict protocol.” 

The clinical trials are crucial as obeldesivir is still experimental for this Ebola strain. It was originally developed as an oral antiviral for COVID-19 and has shown promise against filoviruses, including <a href="https://www.healthandme.com/health-news/dr-congo-is-adding-ebola-treatment-centres-but-faces-health-worker-shortage-as-death-toll-crosses-3700-article-156213337" data-type="tilCustomLink">Bundibugyo virus</a>, in preclinical research.

Also read: <a href="https://www.healthandme.com/health-news/congo-ebola-cases-top-8000-deaths-near-4000-as-treatment-delays-remain-a-concern-article-156247578" data-type="tilCustomLink">Congo Ebola Cases Top 8,000; Deaths Near 4,000 As Treatment Delays Remain A Concern</a>

The EBO-PEP trial began enrolling participants in July 2026, just after WHO experts recommended obeldesivir. By September 18, more than 200 high-risk participants had enrolled. According to latest numbers, there are now more than 250+ people in the trial. 

Gilead donated 2,400 bottles of obeldesivir to support the research. The company also donated remdesivir, which is being made available under a compassionate-use protocol for certain exposed children and pregnant or breastfeeding women who cannot participate in the <a href="https://www.healthandme.com/health-news/dr-congo-says-ebola-outbreak-is-under-control-but-who-warns-virus-is-still-spreading-7000-cases-3398-dead-article-156150126" data-type="tilCustomLink">obeldesivir trial</a>.

The obeldesivir study is separate from the PARTNERS trial, which is testing treatments for people who already have Bundibugyo <a href="https://www.healthandme.com/health/ebola">Ebola</a> disease. That trial is evaluating MBP134, a monoclonal antibody, and remdesivir, including whether the two can be combined to improve survival. WHO launched patient enrolment for the trial in July.

WHO Director-General Dr Tedros Adhanom Ghebreyesus said, “Even without approved therapeutics, people are recovering from this disease, but of course, we could save many more lives with safe and effective therapeutics in our toolkit.”

He added, “The PARTNERS trial, established with national authorities and scientific partners in record time, offers real hope that we can deliver concrete results for – and with – the communities at the heart of the outbreak.” 

The two trials therefore target different stages of infection. PARTNERS is studying treatment after Ebola develops, while <a href="https://www.healthandme.com/health-news/drc-says-ebola-outbreak-has-peaked-un-warns-its-still-growing-article-156162102" data-type="tilCustomLink">EBO-PEP</a> is asking whether obeldesivir can stop disease from developing after exposure.

Rabies Elimination in India: The Biggest Gaps Explained

Participants are monitored closely to see if symptoms could emerge. The trial's goal is to determine whether people who receive obeldesivir are less likely to develop symptomatic <a href="https://www.healthandme.com/health-news/ebola-transmission-falls-in-some-areas-of-congo-but-outbreak-still-kills-who-article-156170590" data-type="tilCustomLink">Bundibugyo Ebola disease</a> than those receiving placebo. Researchers will also assess the drug's safety.

The study is being conducted by ALIMA with the Democratic Republic of Congo's National Institute of Biomedical Research and France's ANRS Emerging Infectious Diseases, alongside other national and international partners.

Health Conditions A-Z

health

congo-ebola-outbreak-obeldesivir-trial-advances-with-250-participants-as-death-toll-crosses-4000

obeldesivir

ebola

obeldesivir trial

bundibugyo ebola

obeldesivir drug

tedros adhanom ghebreyesus

alima

gilead sciences

2026-nobel-medicine-prize-awarded-for-discoveries-on-how-nerve-cells-shape-memory-feelings-and-behaviour

2026 Nobel Medicine Prize Awarded for Discoveries on How Nerve Cells Shape Memory, Feelings and Behaviour

india-made-hpv-vaccine-cervavac-gets-who-prequalification-serum-institute

India-Made HPV Vaccine CERVAVAC Gets WHO Prequalification: Serum Institute

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

An experimental antiviral drug, obeldesivir, is being tested in the Democratic Republic of Congo to assess whether it can prevent Ebola from developing further after a person has been exposed to the virus. As the country continues to fight the deadliest Ebola outbreak, more than 250 people have now enrolled in the EBO-PEP trial, which is testing obeldesivir, an oral antiviral developed by Gilead Sciences. The trial is being conducted in Ituri province, the epicentre where the outbreak caused by the Bundibugyo strain of Ebola is concentrated. According to Congolese health authorities, until now, more than 8,300 confirmed cases and 4,000 deaths across seven provinces have been recorded. More About Obeldesivir Trial Also read: Russia Plague Scare: Lab Worker Dies Of 'Unknown Infection' After Suspected Exposure; CDC Monitors The SituationObeldesivir is not being given to people who are already sick with Ebola in this trial. Instead, researchers are testing it as post-exposure prophylaxis, or PEP. PEP means treating someone after they have been exposed to an infection but before they develop symptoms. The EBO-PEP trial is enrolling people who have had high-risk contact with a confirmed Ebola patient within the previous five days but do not have symptoms. Participants are randomly assigned to receive either obeldesivir or a placebo and are monitored for 21 days, with follow-up continuing to 42 days. The obeldesivir study is designed to include 998 people. The ongoing Ebola outbreak in Ebola is caused by Bundibugyo ebolavirus, a strain for which there is currently no licensed vaccine or approved treatment. In May, WHO experts identified obeldesivir as a candidate for testing as post-exposure prophylaxis. They recommended that it be studied to establish whether it can actually prevent people exposed to the virus from developing Ebola. WHO chief scientist Dr Sylvie Briand said at the time, “This is a promising treatment drug, but it has still to be implemented under a very, very strict protocol.” The clinical trials are crucial as obeldesivir is still experimental for this Ebola strain. It was originally developed as an oral antiviral for COVID-19 and has shown promise against filoviruses, including Bundibugyo virus, in preclinical research. Trial Began Three Months Ago Also read: Congo Ebola Cases Top 8,000; Deaths Near 4,000 As Treatment Delays Remain A ConcernThe EBO-PEP trial began enrolling participants in July 2026, just after WHO experts recommended obeldesivir. By September 18, more than 200 high-risk participants had enrolled. According to latest numbers, there are now more than 250+ people in the trial. Gilead donated 2,400 bottles of obeldesivir to support the research. The company also donated remdesivir, which is being made available under a compassionate-use protocol for certain exposed children and pregnant or breastfeeding women who cannot participate in the obeldesivir trial. The obeldesivir study is separate from the PARTNERS trial, which is testing treatments for people who already have Bundibugyo Ebola disease. That trial is evaluating MBP134, a monoclonal antibody, and remdesivir, including whether the two can be combined to improve survival. WHO launched patient enrolment for the trial in July. WHO Director-General Dr Tedros Adhanom Ghebreyesus said, “Even without approved therapeutics, people are recovering from this disease, but of course, we could save many more lives with safe and effective therapeutics in our toolkit.” He added, “The PARTNERS trial, established with national authorities and scientific partners in record time, offers real hope that we can deliver concrete results for – and with – the communities at the heart of the outbreak.” The two trials therefore target different stages of infection. PARTNERS is studying treatment after Ebola develops, while EBO-PEP is asking whether obeldesivir can stop disease from developing after exposure.                                  Obeldesivir Trial's Goals Participants are monitored closely to see if symptoms could emerge. The trial's goal is to determine whether people who receive obeldesivir are less likely to develop symptomatic Bundibugyo Ebola disease than those receiving placebo. Researchers will also assess the drug's safety. The study is being conducted by ALIMA with the Democratic Republic of Congo's National Institute of Biomedical Research and France's ANRS Emerging Infectious Diseases, alongside other national and international partners.

congo ebola outbreak: obeldesivir trial advances with 250+ participants as death toll crosses 4,000

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Can Obeldesivir Prevent Ebola Symptoms After Exposure? Drug Trial Moves Forward As Death Toll Crosses 4,000

2026 Nobel Medicine Prize Awarded for Discoveries on How Nerve Cells Shape Memory, Feelings and Behaviour

India-Made HPV Vaccine CERVAVAC Gets WHO Prequalification: Serum Institute

COVID-19 May Raise Risk of 6 Allergic Conditions, Study Finds

Health Conditions A-Z

2026 Nobel Medicine Prize Awarded for Discoveries on How Nerve Cells Shape Memory, Feelings and Behaviour

Can Obeldesivir Prevent Ebola Symptoms After Exposure? Drug Trial Moves Forward As Death Toll Crosses 4,000

India-Made HPV Vaccine CERVAVAC Gets WHO Prequalification: Serum Institute